44. Efficacy of Febuxostat Compared to Allopurinol in reducing Hyperuricemia
Akram Munir and Muhammad Akbar
ABSTRACT
Objective: Evaluating the efficacy of Febuxostat in reducing hyperuricemia compared to Allopurinol in adult male.
Study Design: Cross sectional study
Place and Duration of Study: This study was conducted at the Department of Medicine, Isra University Hospital Hyderabad January 2019 – February 2020.
Materials and Methods: A sample of 200 adult healthy male diagnosed cases of systemic hypertension was selected according to the inclusion and exclusion criteria. Subjects were examined physically. Volunteers were asked for blood sampling. Serum Uric acid was estimated at baseline and after 12 weeks of febuxostat and allopurinol therapy. Data was analyzed in SPSS v 21.0 (IBM, Incor, USA) at 95% confidence interval (P ≤ 0.05).
Results: Serum uric acid at baseline was 8.14±1.4 mg/dl. After 12 weeks of Febuxostat and Allopurinol therapy, it was reduced to 2.91±0.75 and 4.2±0.55 mg/dl respectively (F=745.1, P=0.0001). Febuxostat reduced serum uric acid by 64% compared to 48.4% by the Allopurinol
Conclusion: Serum uric acid was reduced by both febuxostat and allopurinol, however, the former was more effective in alleviating hyperuricemia.
Key Words: Uric acid, Febuxostat, Allopurinol, Adult Male
Citation of article: Munir A, Akbar M. Efficacy of Febuxostat Compared to Allopurinol in reducing Hyperuricemia. Med Forum 2020;31(11): 184-187.